Northern New York Newspapers
Watertown
Ogdensburg
Massena-Potsdam
Lowville
Carthage
Malone
NNY Business
NNY Living
NNY Ads
Sun., Nov. 23
ADVERTISE SUBSCRIBE
Serving the communities of Jefferson, St. Lawrence and Lewis counties, New York
In print daily. Online always.
Related Stories

Clarkson professor rings opening bell at New York Stock Exchange

PREV
NEXT
ARTICLE OPTIONS
A A
print this article
e-mail this article

POTSDAM - Prof. Gabor Forgacs, executive and scientific director of Clarkson’s Shipley Center for Innovation and Czanderna and Shirkey Professor in Physics, and the leadership of Organovo rang the opening bell at the New York Stock Exchange, Monday morning, to celebrate its NYSE listing.

A YouTube video of the ceremony is available at http://youtu.be/jqCvThm17cg.

Forgacs is the scientific founder of Organovo, a San Diego-based biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology.

Forgacs is a pioneer of bioprinting, a novel engineering technology to build tissues on demand. He is also the scientific founder of Modern Meadow, a biotech company focused on commercializing tissue engineering technologies for the ethical fabrication of animal products.

Forgacs was on the physics faculty of Clarkson from 1986-2000, returning to Clarkson in 2009, after joining the faculty of the University of Missouri-Columbia as the George H. Vineyard Professor of Biological Physics, where he continues to do research.

Organ printing work was begun at University of Missouri–Columbia in 2004-2005, when a $5 million National Science Foundation Frontiers in Integrative Biological Research (FIBR) grant was awarded to a multi-institution team led by Forgacs. The first patent application for the NovoGen bioprinting platform, Self-Assembling Cell-Aggregates and Methods of Making the Same, was filed by Forgacs and others during the same time frame. In 2007, Organovo Inc. was incorporated with the intent to license the Forgacs patent suite and launch a 3D bioprinting company.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the technology has been featured in The Wall Street Journal, Time, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at http://www.organovo.com.

Commenting rules:
  1. Stick to the topic of the article/letter/editorial.
  2. When responding to issues raised by other commenters, do not engage in personal attacks or name-calling.
  3. Comments that include profanity/obscenities or are libelous in nature will be removed without warning.
Violators' commenting privileges may be revoked indefinitely. By commenting you agree to our full Terms of Use.
Giveaway
Syracuse Football Tickets Giveaway
Connect with Us
WDT News FeedsWDT on FacebookWDT on TwitterWDT on InstagramWDT for iOS: iPad, iPhone, and iPod touchWDT for Android
Showcase of Homes
Showcase of Homes